What Is Monocyte Repartitioning Flow Cytometry for CMML?

Monocyte repartitioning flow cytometry is a specialized laboratory test that can help support a diagnosis of chronic myelomonocytic leukemia (CMML), but it cannot confirm the disease on its own ^[1]. The test typically uses a sample of peripheral blood—the blood drawn from your arm—and uses lasers to identify and count different types of monocytes (a type of white blood cell) based on specific protein markers ^[2].

While people without CMML have a natural mix of three different monocyte types, people with CMML often show a heavily skewed pattern where one specific type takes up a massive share of the population ^[3]. Though this flow cytometry test is a very useful tool, it is just one piece of the diagnostic puzzle and must be combined with a full bone marrow evaluation, genetic testing, and other blood tests to make a definitive diagnosis ^[1].

Understanding Monocyte Subsets

Monocytes are white blood cells that help your immune system fight infections and clean up damaged tissues. Your circulating monocytes are divided into three distinct groups, or “subsets.” Flow cytometry identifies these subsets by looking for the presence of specific proteins—specifically CD14 and CD16—on the surface of the cells ^[3][2].

Even in healthy blood, these three types are not present in equal amounts. Classical monocytes normally make up the largest share, with smaller populations of intermediate and nonclassical monocytes ^[3].

How the Test Supports a CMML Diagnosis

In CMML, the bone marrow produces abnormal monocytes, which changes the natural balance (repartitioning) of the three subsets in the blood ^[3].

Doctors look for a specific pattern: if classical monocytes make up 94% or more of your total monocytes in a peripheral blood sample, this strongly supports a CMML diagnosis ^[3][4]. This 94% threshold is a recognized supporting criterion for CMML when tested in peripheral blood ^[2]. Some specialized laboratories may also use an assay-specific cutoff showing a severe drop in the percentage of nonclassical monocytes as an additional adjunctive finding, though this depends on the exact laboratory method used ^[5][6].

Limitations of Flow Cytometry

While helpful, monocyte repartitioning is not universally definitive. A result at or above 94% does not confirm CMML on its own, and a result below 94% does not rule it out ^[2]. Several factors can skew the results:

• Inflammation and Infection: Conditions like autoimmune diseases or active infections can increase your intermediate monocytes ^[5]. This can push your classical monocyte percentage below the 94% threshold, causing a false negative (the test looks non-CMML, even if you actually have CMML) ^[7][8].
• Other Illnesses: Occasionally, severe infections or other types of cancer can cause reactive monocytosis that mimics the CMML pattern, leading to a false positive (the pattern looks like CMML, but is actually caused by another condition) ^[9][10].
• Blood vs. Bone Marrow: The 94% threshold was validated primarily for peripheral blood ^[2]. Bone marrow has different monocyte distributions, and you cannot simply apply the 94% cutoff to a bone marrow flow cytometry report unless the laboratory has validated its own specific marrow reference range ^[9].
• Sample Quality and Laboratory Expertise: The way the sample is handled and the strict computational rules the laboratory uses to define and count the cells (gating strategy) can significantly change the reported percentages ^[11].
• Previous Treatments: Certain therapies can alter your monocyte proportions, meaning the test is most accurate on blood drawn before starting treatment ^[3]. However, you should never stop or delay prescribed treatments just to get this test; your care team will decide the best timing.

Why It Doesn’t Replace the Full Work-Up

Because of these limitations, monocyte flow cytometry is only a supporting test ^[1]. Your hematologist will interpret the result in the context of your complete clinical picture.

To definitively diagnose CMML, your care team must verify that your monocyte count meets strict criteria: a sustained elevation for at least three months, with an absolute monocyte count of at least $0.5 \times 10^9$/L, and monocytes making up at least 10% of your total white blood cells ^[1].

They must also perform a bone marrow aspirate and core biopsy to look for dysplasia (abnormal development in the blood-forming cells) and confirm that immature leukemia cells (blasts) make up less than 20% of the cells ^[1][12]. Genetic and molecular testing is used to identify acquired mutations (clonality), though a mutation alone does not prove CMML since mutations can occur naturally with age ^[1]. Finally, they must rule out other specific myeloid neoplasms and reactive causes of high monocytes ^[13].